tailieunhanh - Báo cáo y học: "Development of recurrent facial palsy during plasmapheresis in Guillain-Barré syndrome: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Development of recurrent facial palsy during plasmapheresis in Guillain-Barré syndrome: a case report. | Stevenson et al. Journal of Medical Case Reports 2010 4 253 http content 4 1 253 jAg JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Development of recurrent facial palsy during plasmapheresis in Guillain-Barré syndrome a case report Mary L Stevenson1 Louis H Weimer2 Ilya V Bogorad3 Abstract Introduction Guillain-Barré syndrome is an immune-mediated polyneuropathy that is routinely initially treated with either intravenous immunoglobulin or plasmapheresis. To the best of our knowledge no association between plasmapheresis treatment and acute onset of facial neuropathy has been reported. Case presentation A 35-year-old Caucasian man with no significant prior medical history developed ascending motor weakness and laboratory findings consistent with a diagnosis of Guillain-Barré syndrome. Plasmapheresis was initiated. Acute facial palsy developed during the plasma exchange that subsequently resolved and then acutely recurred during the subsequent plasma exchange. Conclusion To the best of our knowledge no prior cases of acute facial palsy developing during plasmapheresis treatment are known. Although facial nerve involvement is common in typical Guillain-Barré syndrome the temporal association with treatment near-complete resolution and later recurrence support the association. The possible mechanism of plasmapheresis-induced worsening of peripheral nerve function in Guillain-Barré syndrome is unknown. Introduction Guillain-Barré syndrome GBS is an immune-mediated acute polyneuropathy typically characterized by ascending weakness and areflexia. An association with Campylobacter jejuni infection is most common however numerous associations are known 1 . Now recognized as a heterogeneous syndrome different variants exist including demyelinating and axonal forms the demyelinating variant is most common in the USA. Based on considerable clinical trial evidence the American Academy of Neurology currently recommends treatment with .